Bridgeway Capital Management’s BioAtla BCAB Stock Holding History

Bridgeway Capital Management’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,800	Closed	-$53.2K	–	1182
2024 Q4	$53.2K	Sell	1,800 -500	-22%	-$42K	﹤0.01%	1152
2024 Q3	$202K	Buy	2,300 +500	+28%	+$41.9K	﹤0.01%	1063
2024 Q2	$123K	Hold	1,800	–	–	﹤0.01%	1142
2024 Q1	$310K	Sell	1,800 -200	-10%	-$24.8K	0.01%	1032
2023 Q4	$246K	Sell	2,000 -240	-11%	-$20.8K	0.01%	1093
2023 Q3	$190K	Buy	2,240 +700	+45%	+$89.2K	﹤0.01%	1111
2023 Q2	$231K	Buy	1,540 +1,100	+250%	+$189K	0.01%	1100
2023 Q1	$59K	Hold	440	–	–	﹤0.01%	1296
2022 Q4	$182K	Hold	440	–	–	﹤0.01%	1108
2022 Q3	$169K	Buy	+440	New	+$144K	﹤0.01%	1167

Other funds holding BCAB

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Bridgeway Capital Management's BCAB Position: Q1 2025 in Review

Bridgeway Capital Management sold out of BioAtla (BCAB) in Q1 2025, closing a stake of 1,800 shares — an estimated $53.2K sold.

Bridgeway Capital Management first reported a position in BCAB in Q3 2022 and held it in 10 quarters. The position peaked at $310K in Q1 2024. 41 funds tracked by Wall St. Rank hold BCAB as of Q1 2025.

Bridgeway Capital Management reported no remaining BioAtla position as of Q1 2025 after selling out during the quarter.
Bridgeway Capital Management sold 1,800 BioAtla shares in Q1 2025, an estimated $53.2K.
Bridgeway Capital Management first reported a position in BioAtla in Q3 2022 and held it in 10 quarters.
Bridgeway Capital Management's BioAtla position peaked at $310K in Q1 2024.
41 funds tracked by Wall St. Rank held BioAtla as of Q1 2025.

Based on Bridgeway Capital Management's 13F filing for Q1 2025, filed 15 May 2025.